Loading patent…
AssigneesAbgenix, Inc., Pfizer Inc.
InventorsBruce D. Cohen, Jean Beebe, Penelope E. Miller, James D. Moyer, Jose R. Corvalan, Michael Gallo
Estimating the term…
The present invention relates to antibodies and antigen-binding portions thereof that specifically bind to insulin-like growth factor I receptor (IGF-IR), which is preferably human IGF-IR. The invention also relates to human anti-IGF-IR antibodies, including chimeric, bispecific, derivatized, single chain antibodies or portions of fusion proteins. The invention also relates to isolated heavy and light chain immunoglobulin molecules derived from anti-IGF-IR antibodies and nucleic acid molecules encoding such molecules. The present invention also relates to methods of making anti-IGF-IR antibodies, pharmaceutical compositions comprising these antibodies and methods of using the antibodies and compositions thereof for diagnosis and treatment. The invention also provides gene therapy methods using nucleic acid molecules encoding the heavy and/or light immunoglobulin molecules that comprise the human anti-IGF-IR antibodies. The invention also relates to gene therapy methods and transgenic animals comprising nucleic acid molecules of the present invention.
A monoclonal antibody that specifically binds insulin-like growth factor I receptor (IGF-IR) or an antigen-binding portion of said antibody, wherein the antibody or portion comprises the amino acid sequences of the CDR1, CDR2 and CDR3 regions found in a variable domain selected from the group consisting of:
A monoclonal antibody or an antigen binding portion thereof that specifically binds insulin-like growth factor I receptor (IGF-IR), wherein said antibody comprises the amino acid sequence in SEQ ID NO:
A monoclonal antibody or an antigen-binding portion thereof that specifically binds insulin like growth factor I receptor (IGF-IR), wherein said antibody comprises the amino acid sequence in SEQ ID NO:
A monoclonal antibody that specifically binds insulin-like growth factor I receptor (IGF-IR), wherein said antibody comprises the amino acid sequence of the heavy chain sequence within SEQ ID NO:
A monoclonal antibody or an antigen-binding portion thereof that specifically binds IGF-IR, comprising the CDR1, CDR2 and CDR3 amino acid sequences, respectively, in SEQ ID NO:45.
A monoclonal antibody that specifically binds IGF-IR comprising the amino acid sequence of SEQ ID NO:
A monoclonal antibody or an antigen binding portion thereof that specifically binds IGF-IR, comprising the CDR1, CDR2 and CDR3 amino acid sequences in SEQ ID NO:
A monoclonal antibody that specifically binds IGF-IR comprising the amino acid sequence in SEQ ID NO:
A monoclonal antibody that specifically binds insulin-like growth factor I receptor (IGF-IR) wherein the heavy chain amino acid sequence is SEQ ID NO:
A hybridoma cell line having American Type Culture Collection (ATCC) accession number PTA-2788.
A monoclonal antibody that specifically binds IGF-IR comprising the heavy chain amino acid sequence and the light chain amino acid sequence of the antibody produced byte hybridoma cell line having ATCC accession number PTA-2788.
A monoclonal antibody that specifically binds IGF-IR comprising the amino acid sequence of the heavy chain and the amino acid sequence of the light chain of antibody 2.13.2.
A monoclonal antibody or antigen-binding portion thereof that specifically binds IGF-IR, comprising a heavy chain amino acid sequence that utilizes a human VH3-23 gene.
A monoclonal antibody or antigen-binding portion thereof that specifically binds IGF-IR, comprising a light chain amino acid sequence that utilizes the VK A30 gene.
The method according to either of claim 99 or 101, further comprising the step of administering an anti-neoplastic, anti-tumor, anti-angiogenic or chemotherapeutic agent.
A monoclonal antibody that specifically binds insulin-like growth factor I receptor (IGF-IR) or an antigen-binding portion of said antibody, wherein the antibody or portion comprises the amino acid sequences of the CDR1, CDR2 and CDR3 regions found in a heavy chain variable domain selected from the group consisting of:
A monoclonal antibody that specifically binds insulin-like growth factor I receptor (IGF-IR) or an antigen-binding portion of said antibody, wherein the antibody or portion comprises the amino acid sequences of the CDR1, CDR2 and CDR3 regions found in the variable domain of a light chain comprising SEQ ID NO:
Dependencies are inferred from the claim text.